Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05226507 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
A Phase 1 study of Ovarian Cancer and Advanced Solid Tumor, sponsored by Nuvectis Pharma.
- Active
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 20
- Study locations
NCT05226507: Active Phase 1 study of Ovarian Cancer and Advanced Solid Tumor, sponsored by Nuvectis Pharma.
NCT05226507 is a Phase 1 study of Ovarian Cancer and Advanced Solid Tumor that is active but no longer recruiting, run by Nuvectis Pharma. The registered enrollment target is 45 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05226507, a Phase 1 study of Ovarian Cancer and Advanced Solid Tumor, is active but no longer recruiting, sponsored by Nuvectis Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
Conditions Studied
Interventions
- DRUG NXP800
Study Locations (20)
Florida
- Florida Cancer Specialists South - Fort Myers
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Florida Cancer Specialists Research North - St. Petersburg
- Florida Cancer Specialists Research East - West Palm Beach
Oklahoma
- OU Health Stephenson Cancer Center - Oklahoma City
- Oklahoma Cancer Specialists and Research Institute - Tulsa
Texas
- Texas Oncology - Fort Worth
- The University of Texas MD Anderson Cancer Center - Houston
Arizona
- Honor Health - Phoenix
California
- UC San Diego Health - Moores Cancer Center - La Jolla
Colorado
- University of Colorado Cancer Center - Aurora
Connecticut
- Yale Gynecologic Oncology - New Haven
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2021-12-31 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT05226507 still lists
NCT05226507 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (94% lower).
The record links to 8 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which NXP800 is the first listed.
NCT05226507 names 20 study sites across 15 states, led by Florida, Oklahoma, Texas.
Frequently Asked Questions
What is clinical trial NCT05226507 about?
NCT05226507 is a clinical study titled "A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer". The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
What is the current status of trial NCT05226507?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2021-12-31. Estimated completion is 2025-12.
What conditions does trial NCT05226507 study?
This clinical trial studies the following conditions: Ovarian Cancer, Advanced Solid Tumor, Ovarian Endometrioid Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Clear Cell Carcinoma.
What interventions are being tested in trial NCT05226507?
The interventions under investigation include: NXP800 (DRUG).
Who is sponsoring clinical trial NCT05226507?
This trial is sponsored by Nuvectis Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05226507 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05226507's enrollment target sits among peer trials
45 219th of 322 higher than 103 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI